Overview: BRCA1 BRCA2 Advanced Panel
Introduction: The BRCA1 BRCA2 Advanced Panel is a diagnostic tool designed to screen for BRCA mutations using whole blood samples. In India, hereditary breast and ovarian cancer syndrome due to BRCA1/BRCA2 mutations affects 5-10 percent of breast cancer cases (higher in young women and familial clusters), with prevalence of pathogenic variants ~1-5 percent in high-risk families. Mutations increase lifetime risk of breast cancer to 45-85 percent and ovarian cancer to 10-40 percent. High morbidity from underdiagnosis in rural/low-SES populations, limited genetic counseling/testing access, cultural stigma around cancer/family history, delayed risk-reducing strategies leading to advanced disease. Per molecular pathology practices aligned with ICMR and Indian Society of Medical Oncology guidelines, the test employs PCR for comprehensive mutation analysis over 1-2 days with high sensitivity/specificity, valuable for identifying carriers to guide screening (mammography/MRI), prophylactic surgery, or PARP inhibitors. This diagnostic falls under genetic cancer screening and targets individuals with family history or early-onset cancer, addressing accurate detection to enable preventive care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating risk management, and reducing hereditary cancer burden. Its whole blood-based approach ensures reliable detection in India's expanding genetic labs.
Other Names: BRCA Adv Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: BRCA discovery in 1990s; in India, prominence with hereditary cancer registries.
Purpose: The test screens for 1 parameter (BRCA1 and BRCA2 mutation analysis) to guide genetic cancer risk assessment, identify carriers, inform preventive strategies.
Test Parameters: 1. BRCA1 and BRCA2 Mutation Analysis.
Pretest Condition: No fasting required; patients should report family history of breast/ovarian cancer or early-onset diagnosis.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Patients should provide details on family cancer history, personal cancer diagnosis, age of onset, or Ashkenazi ancestry.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated mutations including increased cancer risk, benefits of early detection, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive mutations indicate high cancer risk, necessitating specialist input. Negative may require follow-up if family history strong.
Specialist Consultation: Genetic counselors or oncologists should be consulted for management.
Additional Supporting Tests: Family pedigree, tumor testing for confirmation.
Test Limitations: May miss large deletions or variants of uncertain significance; comprehensive approach required.
References: Indian Journal of Medical Genetics 2024, BRCA Studies India 2023.
